Kucharczyk A, Wiesik-Szewczyk E, Poznańska A, et al. - This study was sought to evaluate clinical parameters that are related to the sustained response to omalizumab. Between March 2013 and May 2019, researchers conducted a retrospective, real-life, 4-year follow-up in Poland to evaluate the success of omalizumab based on composed subjective and objective criteria. They conducted simple/multiple regression analyses to search for predictors of the response to omalizumab. In the analysis, for omalizumab therapy, a total of 989 severe allergic asthma individuals were referred, of whom 854 patients were considered eligible for treatment. Omalizumab therapy was found to be very effective, with this effectiveness sustained after 4 years of treatment. It was shown that at week 16, the success of the therapy can be predicted from the baseline FEV1% and clinical improvement (based on ACQ-7 and miniAQLQ scores).